These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 17687916)
21. Aqueous humor dynamics and implications for clinical practice. Malihi M; Sit AJ Int Ophthalmol Clin; 2011; 51(3):119-39. PubMed ID: 21633243 [No Abstract] [Full Text] [Related]
22. A history of glaucoma pharmacology. Realini T Optom Vis Sci; 2011 Jan; 88(1):36-8. PubMed ID: 21131876 [TBL] [Abstract][Full Text] [Related]
23. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Stoner A; Harris A; Oddone F; Belamkar A; Verticchio Vercellin AC; Shin J; Januleviciene I; Siesky B Br J Ophthalmol; 2022 Oct; 106(10):1332-1337. PubMed ID: 34433550 [TBL] [Abstract][Full Text] [Related]
29. The effect of antiglaucoma drugs on rabbit aqueous humor proteins determined by gel electrophoresis. Reyes MR; Cheng Q; Chuang PY; Lee DA J Ocul Pharmacol Ther; 1998 Jun; 14(3):229-37. PubMed ID: 9671430 [TBL] [Abstract][Full Text] [Related]
30. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Christiansen GA; Nau CB; McLaren JW; Johnson DH Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319 [TBL] [Abstract][Full Text] [Related]
31. [Effect of preoperative use of carbonic anhydrase inhibitors on the development of filtering cicatrix]. Zolog N; Chercota G Bull Mem Soc Fr Ophtalmol; 1968; 81():493-504. PubMed ID: 5759766 [No Abstract] [Full Text] [Related]
32. [Treatment of glaucoma with beta receptor blockers. Significance of adrenergic receptors of the beta-2 subtype for their effect on intraocular pressure]. Noack E Ophthalmologica; 1988; 196(2):76-81. PubMed ID: 2896327 [TBL] [Abstract][Full Text] [Related]
33. [Primary open angle glaucoma. Morphological bases for the understanding of the pathogenesis and effects of antiglaucomatic substances]. Lütjen-Drecoll E; Kruse FE Ophthalmologe; 2007 Feb; 104(2):167-78; quiz 179. PubMed ID: 17242882 [TBL] [Abstract][Full Text] [Related]
34. Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. Donegan RK; Lieberman RL J Med Chem; 2016 Feb; 59(3):788-809. PubMed ID: 26356532 [TBL] [Abstract][Full Text] [Related]
35. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion. Brechue WF; Maren TH Exp Eye Res; 1993 Jul; 57(1):67-78. PubMed ID: 8405174 [TBL] [Abstract][Full Text] [Related]
36. Pharmacological therapy for glaucoma: a review. Hoyng PF; van Beek LM Drugs; 2000 Mar; 59(3):411-34. PubMed ID: 10776828 [TBL] [Abstract][Full Text] [Related]
37. Regulation of Aqueous Humor Dynamics by Hydrogen Sulfide: Potential Role in Glaucoma Pharmacotherapy. Ohia SE; Robinson J; Mitchell L; Ngele KK; Heruye S; Opere CA; Njie-Mbye YF J Ocul Pharmacol Ther; 2018; 34(1-2):61-69. PubMed ID: 29215951 [TBL] [Abstract][Full Text] [Related]
38. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA; Wilde MI Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858 [TBL] [Abstract][Full Text] [Related]
39. A risk-benefit assessment of drugs used in the management of glaucoma. Taniguchi T; Kitazawa Y Drug Saf; 1994 Jul; 11(1):68-74. PubMed ID: 7917081 [TBL] [Abstract][Full Text] [Related]
40. Observations on the pharmacology of glaucoma. Leopold IH; Duzman E Annu Rev Pharmacol Toxicol; 1986; 26():401-26. PubMed ID: 2872854 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]